Clinical trial · Expanded Access
Managed Access Programs for INC424, Ruxolitinib
NCT04745637CI-TRIAL-00097464availableClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this registration is to list Managed Access Programs (MAPs) related to INC424, Ruxolitinib
Conditions
Conditions (7)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Polycythemia Vera (PV) | Polycythemia Vera | ONTOLOGY_EXACT | 0.85 |
| Post Polycythemia Myelofibrosis (PPV MF) | — | UNRESOLVED | — |
| Primary Myelofibrosis (PMF) | Primary Myelofibrosis | ONTOLOGY_EXACT | 0.85 |
| Severe/Very Severe COVID-19 Illness | — | UNRESOLVED | — |
| Steroid Refractory Acute Graft Versus Host Disease (SR aGVHD) | — | UNRESOLVED | — |
| Steroid Refractory Chronic Graft Versus Host Disease (SR cGVHD) | — | UNRESOLVED | — |
| Thrombocythemia Myelofibrosis (PET-MF) | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ruxolitinib | Drug | Ruxolitinib | ALIAS |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 2 Years
Show eligibility criteria text
Inclusion criteria 1. An independent request was received from a licensed physician. 2. The patient has a serious or life-threatening disease or condition and there is no comparable or satisfactory alternative therapy available for diagnosis, monitoring, or treatment. 3. The patient is not eligible or able to enroll in a clinical trial or continue participation in such trial. 4. There is a potential patient benefit to justify the potential risk of the treatment use, and the potential risk is not unreasonable in the context of the disease or condition to be treated. 5. The patient must meet any other medical criteria established by the medical experts responsible for the product or by the health authority in the country of request (as applicable). 6. Provision of the product will not interfere with the initiation, conduct, or completion of a Novartis clinical trial or overall development program. 7. Managed Access provision is allowed per local laws/regulations.
References
Publications (0)
Data not yet available
No reference posted for this study.